{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:33:09Z","timestamp":1764401589901},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T00:00:00Z","timestamp":1357776000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s12032-012-0440-4","type":"journal-article","created":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T11:53:37Z","timestamp":1357732417000},"source":"Crossref","is-referenced-by-count":8,"title":["Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer"],"prefix":"10.1007","volume":"30","author":[{"given":"Xianglin L.","family":"Du","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan C.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Lairson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon H.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Putao","family":"Cen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,1,10]]},"reference":[{"issue":"suppl","key":"440_CR1","first-page":"S4","volume":"55","author":"National Institutes of Health","year":"1994","unstructured":"National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: ovarian cancer\u2014screening, treatment and follow-up. Gynecol Oncol. 1994;55(suppl):S4\u201314.","journal-title":"Gynecol Oncol"},{"key":"440_CR2","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519\u201329.","journal-title":"N Engl J Med"},{"issue":"10 Suppl","key":"440_CR3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1200\/JCO.2003.04.003","volume":"21","author":"SA Cannistra","year":"2003","unstructured":"Cannistra SA, Bast RC Jr, Berek JS, et al. Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol. 2003;21(10 Suppl):129\u201332.","journal-title":"J Clin Oncol"},{"key":"440_CR4","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1136\/bmj.303.6807.884","volume":"303","author":"Advanced Ovarian Cancer Trialists Group","year":"1991","unstructured":"Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. BMJ. 1991;303:884\u201393.","journal-title":"BMJ"},{"key":"440_CR5","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/cncr.20126","volume":"100","author":"J Hugosson","year":"2004","unstructured":"Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer. 2004;100:1397\u2013405.","journal-title":"Cancer"},{"key":"440_CR6","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/13543784.10.9.1715","volume":"10","author":"M Harries","year":"2001","unstructured":"Harries M, Kaye SB. Recent advances in the treatment of epithelial ovarian cancer. Expert Opin Investig Drugs. 2001;10:1715\u201324.","journal-title":"Expert Opin Investig Drugs"},{"key":"440_CR7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1470-2045(02)00846-X","volume":"3","author":"M Harries","year":"2002","unstructured":"Harries M, Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol. 2002;3:529\u201336.","journal-title":"Lancet Oncol"},{"key":"440_CR8","first-page":"426","volume":"50","author":"A Berkenblit","year":"2005","unstructured":"Berkenblit A, Cannistra SA. Advances in the management of epithelial ovarian cancer. J Reprod Med. 2005;50:426\u201338.","journal-title":"J Reprod Med"},{"key":"440_CR9","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/jnci\/djj443","volume":"98","author":"M Kyrgiou","year":"2006","unstructured":"Kyrgiou M, Salanti G, Pavlidis N, Paraskevaidis E, Ioannidis JP. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst. 2006;98:1655\u201363.","journal-title":"J Natl Cancer Inst"},{"issue":"20","key":"440_CR10","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1200\/JCO.2007.11.1013","volume":"25","author":"C Trop\u00e9","year":"2007","unstructured":"Trop\u00e9 C, Kaern J. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature. J Clin Oncol. 2007;25(20):2909\u201320. (Review).","journal-title":"J Clin Oncol"},{"issue":"2","key":"440_CR11","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ygyno.2009.04.023","volume":"114","author":"HO Smith","year":"2009","unstructured":"Smith HO, Moon J, Wilczynski SP, et al. Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer. Gynecol Oncol. 2009;114(2):206\u20139.","journal-title":"Gynecol Oncol"},{"key":"440_CR12","first-page":"CD007565","volume":"8","author":"A Elattar","year":"2011","unstructured":"Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;8:CD007565.","journal-title":"Cochrane Database Syst Rev"},{"key":"440_CR13","first-page":"CD005342","volume":"6","author":"DD Rosa","year":"2012","unstructured":"Rosa DD, Medeiros LR, Edelweiss MI, Pohlmann PR, Stein AT. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev. 2012;6:CD005342.","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"440_CR14","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1002\/cncr.26610","volume":"118","author":"A Alvarez Secord","year":"2012","unstructured":"Alvarez Secord A, Berchuck A, Higgins RV, et al. A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Cancer. 2012;118(13):3283\u201393.","journal-title":"Cancer"},{"key":"440_CR15","unstructured":"National Cancer Institute. Ovarian epithelial cancer treatment (PDQ\u00ae). http:\/\/www.cancer.gov\/cancertopics\/pdq\/treatment\/ovarianepithelial\/HealthProfessional . Accessed 5 Oct 2012."},{"issue":"2","key":"440_CR16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2007.06.029","volume":"107","author":"LJ Havrilesky","year":"2007","unstructured":"Havrilesky LJ, Secord AA, Kulasingam S, Myers E. Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. Gynecol Oncol. 2007;107(2):211\u20138.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"440_CR17","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ygyno.2007.05.043","volume":"106","author":"RE Bristow","year":"2007","unstructured":"Bristow RE, Santillan A, Salani R, et al. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis. Gynecol Oncol. 2007;106(3):476\u201381.","journal-title":"Gynecol Oncol"},{"issue":"25","key":"440_CR18","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1200\/JCO.2007.13.1961","volume":"26","author":"LJ Havrilesky","year":"2008","unstructured":"Havrilesky LJ, Secord AA, Darcy KM, Armstrong DK, Gynecologic Oncology Group. Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2008;26(25):4144\u201350.","journal-title":"J Clin Oncol"},{"issue":"1","key":"440_CR19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/107327481101800109","volume":"18","author":"GP Sfakianos","year":"2011","unstructured":"Sfakianos GP, Havrilesky LJ. A review of cost-effectiveness studies in ovarian cancer. Cancer Control. 2011;18(1):59\u201364.","journal-title":"Cancer Control"},{"issue":"10","key":"440_CR20","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2010.32.1075","volume":"29","author":"DE Cohn","year":"2011","unstructured":"Cohn DE, Kim KH, Resnick KE, O\u2019Malley DM, Straughn JM Jr. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol. 2011;29(10):1247\u201351.","journal-title":"J Clin Oncol"},{"issue":"2","key":"440_CR21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/cncr.26199","volume":"118","author":"LJ Havrilesky","year":"2012","unstructured":"Havrilesky LJ, Pokrzywinski R, Revicki D, et al. Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer. Cancer. 2012;118(2):386\u201391.","journal-title":"Cancer"},{"key":"440_CR22","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/1097-0142(19950915)76:6<1096::AID-CNCR2820760626>3.0.CO;2-4","volume":"76","author":"HE Averette","year":"1995","unstructured":"Averette HE, Janicek MF, Menck HR. The National Cancer Data Base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1995;76:1096\u2013103.","journal-title":"Cancer"},{"key":"440_CR23","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1002\/(SICI)1097-0142(19961115)78:10<2236::AID-CNCR28>3.0.CO;2-Z","volume":"78","author":"EE Partridge","year":"1996","unstructured":"Partridge EE, Phillips JL, Menck HR. National Cancer Data Base report on ovarian cancer treatment in United States hospitals. Cancer. 1996;78:2236\u201346.","journal-title":"Cancer"},{"key":"440_CR24","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1200\/JCO.1997.15.11.3408","volume":"15","author":"KA Munoz","year":"1997","unstructured":"Munoz KA, Harlan LC, Trimble EL. Patterns of care for women with ovarian cancer in the United States. J Clin Oncol. 1997;15:3408\u201315.","journal-title":"J Clin Oncol"},{"key":"440_CR25","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/(SICI)1097-0142(19970815)80:4<816::AID-CNCR21>3.0.CO;2-V","volume":"80","author":"G Parham","year":"1997","unstructured":"Parham G, Phillips JL, Hicks ML, et al. The National Cancer Data Base report on malignant epithelial ovarian carcinoma in African-American women. Cancer. 1997;80:816\u201326.","journal-title":"Cancer"},{"key":"440_CR26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1200\/JCO.20.1.173","volume":"20","author":"V Sundararajan","year":"2002","unstructured":"Sundararajan V, Hershman D, Grann VR, Jacobson JS, Neugut AI. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol. 2002;20:173\u20138.","journal-title":"J Clin Oncol"},{"key":"440_CR27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1006\/gyno.2002.6743","volume":"86","author":"C Kosary","year":"2002","unstructured":"Kosary C, Trimble EL. Treatment and survival for women with Fallopian tube carcinoma: a population-based study. Gynecol Oncol. 2002;86:190\u20131.","journal-title":"Gynecol Oncol"},{"key":"440_CR28","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2003.08.065","volume":"21","author":"RD Cress","year":"2003","unstructured":"Cress RD, O\u2019Malley CD, Leiserowitz GS, Campleman SL. Patterns of chemotherapy use for women with ovarian cancer: a population-based study. J Clin Oncol. 2003;21:1530\u20135.","journal-title":"J Clin Oncol"},{"key":"440_CR29","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1200\/JCO.2003.01.061","volume":"21","author":"LC Harlan","year":"2003","unstructured":"Harlan LC, Clegg LX, Trimble EL. Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol. 2003;21:3488\u201394.","journal-title":"J Clin Oncol"},{"issue":"10 Suppl","key":"440_CR30","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1002\/cncr.11339","volume":"97","author":"MT Goodman","year":"2003","unstructured":"Goodman MT, Howe HL. Descriptive epidemiology of ovarian cancer in the United States, 1992\u20131997. Cancer. 2003;97(10 Suppl):2615\u201330.","journal-title":"Cancer"},{"key":"440_CR31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2003.10.006","volume":"92","author":"D Hershman","year":"2004","unstructured":"Hershman D, Fleischauer AT, Jacobson JS, Grann VR, Sundararajan V, Neugut AI. Patterns and outcomes of chemotherapy for elderly patients with stage II ovarian cancer: a population-based study. Gynecol Oncol. 2004;92:293\u20139.","journal-title":"Gynecol Oncol"},{"key":"440_CR32","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ygyno.2004.04.022","volume":"94","author":"D Hershman","year":"2004","unstructured":"Hershman D, Jacobson JS, McBride R, et al. Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol. 2004;94:540\u20139.","journal-title":"Gynecol Oncol"},{"key":"440_CR33","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ygyno.2006.08.010","volume":"103","author":"BA Goff","year":"2006","unstructured":"Goff BA, Matthews BJ, Wynn M, et al. Ovarian cancer: patterns of surgical care across the United States. Gynecol Oncol. 2006;103:383\u201390.","journal-title":"Gynecol Oncol"},{"key":"440_CR34","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/sj.bjc.6603457","volume":"95","author":"JK Chan","year":"2006","unstructured":"Chan JK, Urban R, Cheung MK, et al. Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer. 2006;95:1314\u201320.","journal-title":"Br J Cancer"},{"key":"440_CR35","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ygyno.2006.03.052","volume":"103","author":"L Elit","year":"2006","unstructured":"Elit L, Chartier C, Oza A, et al. Outcomes for systemic therapy in women with ovarian cancer. Gynecol Oncol. 2006;103:554\u20138.","journal-title":"Gynecol Oncol"},{"key":"440_CR36","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1111\/j.1475-6773.2006.00596.x","volume":"41","author":"D Polsky","year":"2006","unstructured":"Polsky D, Armstrong KA, Randall TC, et al. Variation in chemotherapy utilization in ovarian cancer: the relative contribution of geography. Health Serv Res. 2006;41:2201\u201318.","journal-title":"Health Serv Res"},{"key":"440_CR37","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/jnci\/djj019","volume":"98","author":"CC Earle","year":"2006","unstructured":"Earle CC, Schrag D, Neville BA, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst. 2006;98:172\u201380.","journal-title":"J Natl Cancer Inst"},{"key":"440_CR38","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.2006.08.2933","volume":"25","author":"JH Silber","year":"2007","unstructured":"Silber JH, Rosenbaum PR, Polsky D, et al. Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy? J Clin Oncol. 2007;25:1169\u201375.","journal-title":"J Clin Oncol"},{"key":"440_CR39","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1002\/cncr.25242","volume":"116","author":"KM Fairfield","year":"2010","unstructured":"Fairfield KM, Lucas FL, Earle CC, Small L, Trimble EL, Warren JL. Regional variation in cancer-directed surgery and mortality among women with epithelial ovarian cancer in the medicare population. Cancer. 2010;116:4840\u20138.","journal-title":"Cancer"},{"key":"440_CR40","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ygyno.2011.03.022","volume":"122","author":"MM Thrall","year":"2011","unstructured":"Thrall MM, Gray HJ, Symons RG, Weiss NS, Flum DR, Goff BA. Trends in treatment of advanced epithelial ovarian cancer in the medicare population. Gynecol Oncol. 2011;122:100\u20136.","journal-title":"Gynecol Oncol"},{"key":"440_CR41","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2010.34.1552","volume":"29","author":"KM Fairfield","year":"2011","unstructured":"Fairfield KM, Murray K, Lucas FL, et al. Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer. J Clin Oncol. 2011;29:3921\u20136.","journal-title":"J Clin Oncol"},{"key":"440_CR42","unstructured":"National Cancer Institute. About the SEER (Surveillance Epidemiology and End Results) Registries. http:\/\/seer.cancer.gov\/registries\/ . Accessed 15 Sept 2012."},{"key":"440_CR43","unstructured":"Parsons LS. Reducing bias in a propesnity score matching-pair sample using greedymatching techniques, available at http:\/\/www2.sas.com\/proceedings\/sugi26\/p214-26.pdf . Accessed 2 July 2012."},{"key":"440_CR44","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1525-1438.2007.01081.x","volume":"18","author":"XL Du","year":"2008","unstructured":"Du XL, Sun CC, Milam MR, Bodurka DC, Fang S. Ethnic differences in socioeconomic status, diagnosis, treatment and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18:660\u20139.","journal-title":"Int J Gynecol Cancer"},{"key":"440_CR45","unstructured":"U.S. Public Health Services. International classification of diseases, 9th revision, clinical modification. 5th ed. Los Angeles, CA: Practice Management Information Corporation; 1996."},{"key":"440_CR46","volume-title":"Physicians\u2019 current procedural terminology-CPT 2000","author":"American Medical Association","year":"2000","unstructured":"American Medical Association. Physicians\u2019 current procedural terminology-CPT 2000. Chicago, IL: American Medical Association; 2000."},{"key":"440_CR47","volume-title":"HCFA common procedure coding system: national level II medicare codes","author":"Health Care Financing Administration","year":"2000","unstructured":"Health Care Financing Administration. HCFA common procedure coding system: national level II medicare codes. Los Angeles, CA: Practice Management Information Corporation; 2000."},{"key":"440_CR48","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1200\/JCO.2001.19.5.1455","volume":"19","author":"XL Du","year":"2001","unstructured":"Du XL, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from medicare claims data. J Clin Oncol. 2001;19:1455\u201361.","journal-title":"J Clin Oncol"},{"key":"440_CR49","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/01.mlr.0000196978.34283.a6","volume":"44","author":"XL Du","year":"2006","unstructured":"Du XL, Key CR, Dickie L, et al. External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews. Med Care. 2006;44:124\u201331.","journal-title":"Med Care"},{"key":"440_CR50","doi-asserted-by":"crossref","unstructured":"Lund JL, St\u00fcrmer T, Harlan LC, et al. Identifying specific chemotherapeutic agents in medicare data: a validation study. Med Care. 2011 Nov 10. [Epub ahead of print].","DOI":"10.1097\/MLR.0b013e31823ab60f"},{"key":"440_CR51","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"440_CR52","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0895-4356(93)90103-8","volume":"46","author":"PS Romano","year":"1993","unstructured":"Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075\u20139.","journal-title":"J Clin Epidemiol"},{"key":"440_CR53","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","volume":"53","author":"CN Klabunde","year":"2000","unstructured":"Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258\u201367.","journal-title":"J Clin Epidemiol"},{"key":"440_CR54","unstructured":"National Cancer Institute. SEER-medicare: calculation of comorbidity weights. http:\/\/healthservices.cancer.gov\/seermedicare\/program\/comorbidity.html . Accessed 18 July 2012."},{"key":"440_CR55","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1200\/JCO.2002.05.088","volume":"20","author":"XL Du","year":"2002","unstructured":"Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol. 2002;20:4636\u201342.","journal-title":"J Clin Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-012-0440-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-012-0440-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-012-0440-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T23:35:05Z","timestamp":1562542505000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-012-0440-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,10]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["440"],"URL":"https:\/\/doi.org\/10.1007\/s12032-012-0440-4","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,10]]},"article-number":"440"}}